Results 81 to 90 of about 43,558 (239)

PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]

open access: yes, 2015
Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T   +14 more
core   +1 more source

SLPI/FBW7/c‐Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity

open access: yesCancer Science, EarlyView.
SLPI reduces the sensitivity of PDAC to gemcitabine by competing with FBW7 for binding to c‐Myc, thereby disrupting FBW7‐dependent ubiquitination and proteasomal degradation of c‐Myc, leading to increased c‐Myc stability and expression. SLPI knockdown could significantly increase gemcitabine sensitivity to gemcitabine‐induced direct cytotoxicity and NK
Haofei Chen   +7 more
wiley   +1 more source

Struma Ovarii Associated with Ascites and Elevated CA125: Two Case Reports and Review of the Literature

open access: yesInternational Journal of Women's Health, 2022
Shaoyu Wang, Xinqin He, Huijuan Yang, Lihong Chen Department of Obstetrics and Gynecology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, People’s Republic of ChinaCorrespondence: Lihong Chen, Department of Obstetrics and ...
Wang S, He X, Yang H, Chen L
doaj  

A Second Look or, Not to Mention the Occasional Capsizing of a Windsurfer [PDF]

open access: yes, 1994
Of all of the epithelial ovarian cancers (EOC), clear cell adenocarcinoma (CCA) has the worst clinical prognosis. Furthermore, the conventional EOC biomarker CA125 is more often negative in CCA than in other subtypes of EOC. This study sought to discover
Ayako Nomura (1903456)   +8 more
core   +4 more sources

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐TAIL‐2

open access: yesCancer Science, EarlyView.
BLURB FOR ETOC: The J‐TAIL‐2 study (NCT04501497) evaluated the efficacy and safety of atezolizumab, an anti‐programmed death‐ligand 1, plus chemotherapy in patients with non‐small cell lung cancer (NSCLC) and extensive‐stage small cell lung cancer (ES‐SCLC) in real‐world settings.
Yasushi Goto   +19 more
wiley   +1 more source

Biochemical markers in cancer of the ovary : a review [PDF]

open access: yes, 1990
The ideal tumour marker would be one which is detectable before obvious clinical involvement. A number of biochemical markers have been used to diagnose carcinoma of the ovary.
Cauchi, Maurice N.
core  

Change-point of multiple biomarkers in women with ovarian cancer [PDF]

open access: yes, 2017
To date several algorithms for longitudinal analysis of ovarian cancer biomarkers have been proposed in the literature. An issue of specific interest is to determine whether the baseline level of a biomarker changes significantly at some time instant ...
Blyuss, O   +9 more
core   +1 more source

Cervical Small Cell Neuroendocrine Carcinoma Initially Detected on Cytology: Diagnostic Pitfalls and Clues

open access: yesCytopathology, EarlyView.
This case describes the initial detection of cervical small cell neuroendocrine carcinoma on conventional endometrial and cervicovaginal liquid‐based cytology. Given its rarity and high aggressiveness, early recognition and rapid, intensive treatment are crucial for improving patient outcomes.
Yesul Jeong
wiley   +1 more source

Association between serum CA125 levels in preeclampsia and its severity among women in Lagos, South-West Nigeria

open access: yesHypertension in Pregnancy, 2018
Background: Preeclampsia is a syndrome of unknown etiology characterized by hypertension, proteinuria, and/or organ dysfunction. CA125 is an antigenic determinant recognized by the murine monoclonal antibody OC125 quantified by radioimmunoassay. Its role
Gbemisola E. Osanyin   +2 more
doaj   +1 more source

Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests [PDF]

open access: yes, 2011
Background: We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer.Methods: 545 women with a positive family history of ...
Marielle AE Nobbenhuis   +16 more
core   +2 more sources

Home - About - Disclaimer - Privacy